What's Happening?
Delcath Systems, Inc., an interventional oncology company, has commenced dosing the first patient in its Phase 2 clinical trial of HEPZATO at the European Institute of Oncology in Milan, Italy. This trial aims to evaluate the safety and efficacy of HEPZATO in combination
with standard care treatments for patients with liver-dominant HER2-negative metastatic breast cancer. The trial will enroll approximately 90 patients across more than 20 sites in the U.S. and Europe, focusing on hepatic progression-free survival as the primary endpoint. Delcath's HEPZATO KIT, which combines the chemotherapeutic drug melphalan with a proprietary Hepatic Delivery System, is designed to deliver high-dose chemotherapy directly to the liver while minimizing systemic exposure.
Why It's Important?
The initiation of this trial is significant as it addresses the unmet needs of patients with liver-dominant metastatic breast cancer, a condition affecting around 7,000 patients annually in the U.S. These patients often have limited treatment options, and liver metastases are a primary cause of mortality. Delcath's approach could offer a novel therapeutic alternative, potentially improving survival rates and quality of life for affected individuals. The trial also represents a strategic expansion of Delcath's clinical investigations beyond metastatic uveal melanoma, potentially broadening the application of its hepatic delivery system platform.
What's Next?
As the trial progresses, Delcath will continue to engage with clinical sites and educate physicians on liver-directed therapy. The company aims to advance the evaluation of HEPZATO's potential benefits in oncology, with the possibility of expanding its use to other cancer types. Regulatory review and approval processes will be critical in determining the future commercial availability of HEPZATO for broader applications.
